Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 308.3 INR 0.85% Market Closed
Market Cap: 139.7B INR
Have any thoughts about
Marksans Pharma Ltd?
Write Note

Marksans Pharma Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Marksans Pharma Ltd
Cost of Revenue Peer Comparison

Comparables:
DRREDDY
CIPLA
SUNPHARMA
T
TORNTPHARM
M
MANKIND

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Marksans Pharma Ltd
NSE:MARKSANS
Cost of Revenue
-â‚ą10.6B
CAGR 3-Years
-20%
CAGR 5-Years
-16%
CAGR 10-Years
-10%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cost of Revenue
-â‚ą84.5B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cost of Revenue
-â‚ą87.5B
CAGR 3-Years
-3%
CAGR 5-Years
-9%
CAGR 10-Years
-8%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cost of Revenue
-â‚ą104.9B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cost of Revenue
-â‚ą27.5B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
M
Mankind Pharma Ltd
NSE:MANKIND
Cost of Revenue
-â‚ą34B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Marksans Pharma Ltd's Cost of Revenue?
Cost of Revenue
-10.6B INR

Based on the financial report for Jun 30, 2024, Marksans Pharma Ltd's Cost of Revenue amounts to -10.6B INR.

What is Marksans Pharma Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-10%

Over the last year, the Cost of Revenue growth was -11%. The average annual Cost of Revenue growth rates for Marksans Pharma Ltd have been -20% over the past three years , -16% over the past five years , and -10% over the past ten years .

Back to Top